Pharmaceutical commercial stocks are repeatedly active, NEPTUNUS has a 6-day consecutive limit-up, Realcan hits the limit-up, HRPC, SHKK, INT'L GROUP, and others follow suit. In news, China's drug price registration system has officially launched

Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Announces Date for Extraordinary General Meeting

Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. will hold an extraordinary general meeting on 23 December 2025 in Shenzhen, China, to consider and pass an ordinary resolution. The original content was published via the Issuer Information Service of the Hong Kong Stock Exchange on November 24, 2025.

NEPTUNUS: HW130 injection completed Phase I clinical trial

NEPTUNUS announced that its wholly-owned subsidiary has completed Phase I clinical trials for the HW130 injection and obtained the Phase I clinical research report. HW130 is a novel anti-tumor drug with independent intellectual property rights, and has received clinical trial approval from the National Medical Products Administration and the U.S. FDA. The drug has shown good safety and tolerability in patients with advanced malignant solid tumors, providing a basis for subsequent clinical trials

NEPTUNUS terminates the matter of change in control

NEPTUNUS announced the termination of the change of control matter and the cancellation of relevant agreements with Silk Spun Group and NEPTUNUS Group. At the same time, the company decided to terminate the issuance of A-shares to specific objects and signed an agreement to terminate the share subscription agreement

The pharmaceutical commercial sector has seen a short-term surge, with YIXINTANG hitting the limit up

The pharmaceutical commercial sector saw a short-term surge, with YIXINTANG hitting the limit up, and Sinopharm Accord, NEPTUNUS, INT'L GROUP, ZHEJIANG ZHENYUAN, CQP, and others all rising